CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX) Files An 8-K Other Events

ME Staff 8-k
-
0
CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX) Files An 8-K Other Events

CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX) Files An 8-K Other Events
Item 8.01 Other Events

On September 13, 2019, the Company issued a press release announcing that it had determined not to conclude its planned offering of common stock announced on September 11, 2019. The Company believes that the culmination of an offering at the current market price of the common stock is not in the best interest of the Company and its stockholders. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

99.1    Press release issued by the Company on September 13, 2019.

2


CATALYST PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 d804462dex991.htm EX-99.1 EX-99.1 Exhibit 99.1     FOR IMMEDIATE RELEASE Catalyst Pharmaceuticals,…
To view the full exhibit click here

About CATALYST PHARMACEUTICALS, INC. (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company’s Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company’s CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette’s Disorder. The Company’s CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette’s Disorder, and epilepsy.